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Menopausal symptoms are the main reason women
use post-menopausal hormonal therapy. Clinical studies
have established that tibolone exerts a beneﬁcial oes-
trogenic impact with regard to hot ﬂushes and vaginal
dryness.
Tibolone is structurally related to the 19-nortestos-
terone progestins used clinically in oral contraceptives,
but its activity depends on how it is metabolised by
humans and non-human primates. Its three main bio-
logically active metabolites are the 3a-hydroxy (3a-OH)
metabolite and the 3b-hydroxy (3b-OH) metabolite,
which have oestrogen agonist properties, and the D-4
ketoisomer which has progestogenic and androgenic
eﬀects.
Tibolone’s conversion into metabolites occurs chieﬂy
in the liver and intestine, but important tissue-selective
eﬀects are explained by speciﬁc local-tissue metabolism.
The D-4 isomer is produced primarily within the endo-
metrium, binds to the progesterone receptor, and
thereby protects the endometrium from the agonist
eﬀects of the two oestrogenic metabolites.
As a consequence, tibolone does not cause endome-
trial proliferation. This protective eﬀect has been docu-
mented in long-term (up to 8 years) human studies. Its
endometrial safety is comparable to that achieved with
continuous combined oestrogen–progestin regimens, but
with a lower rate of breakthrough bleeding. In addition,
amenorrhoea is achieved more rapidly, since 90% of
tibolone-treated women are amenorrhoeic by 6 months.
Altogether, many studies indicate that tibolone is an
appropriate choice for hormonal therapy, suitable for
most post-menopausal women.
Evidence to date, in human and monkey studies
suggests that tibolone provides an adequate safety with
regard to its eﬀects on the endometrium and is a wel-
come addition to the classical oestrogen + progestin
hormonal treatment available for post-menopausal
women.
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